Today Biotime Incorporated (NYSEMKT:BTX) Reported Increase in Shorted Shares

September 17, 2017 - By Henry Gaston

 Today Biotime Incorporated (NYSEMKT:BTX) Reported Increase in Shorted Shares

Investors sentiment decreased to 2.65 in Q4 2016. Its down 0.02, from 2.67 in 2016Q3. It turned negative, as 4 investors sold BioTime, Inc. shares while 13 reduced holdings. 12 funds opened positions while 33 raised stakes. 40.36 million shares or 3.11% more from 39.14 million shares in 2016Q3 were reported.
Blackrock Incorporated reported 0% in BioTime, Inc. (NYSEMKT:BTX). Manufacturers Life Ins Com The stated it has 52,921 shares. Moreover, Family Management Corporation has 0.28% invested in BioTime, Inc. (NYSEMKT:BTX). Moreover, Jane Street Group Ltd Co has 0% invested in BioTime, Inc. (NYSEMKT:BTX) for 77,605 shares. Broadwood Capital holds 24.90 million shares or 15.24% of its portfolio. Pnc Financial Svcs Grp Incorporated owns 80,300 shares or 0% of their US portfolio. Principal Fincl Gp has invested 0% in BioTime, Inc. (NYSEMKT:BTX). Carroll Fin Inc holds 17,000 shares or 0.01% of its portfolio. The Switzerland-based Credit Suisse Ag has invested 0% in BioTime, Inc. (NYSEMKT:BTX). Blackrock Management Ltd Liability Company accumulated 278,470 shares. Deutsche Bank Ag invested in 41,189 shares. Cambridge Inv Advsr invested in 0% or 18,605 shares. State Common Retirement Fund reported 47,500 shares. Huntington Bank reported 0% in BioTime, Inc. (NYSEMKT:BTX). Vanguard Grp has invested 0% in BioTime, Inc. (NYSEMKT:BTX).

Since May 16, 2017, it had 1 buying transaction, and 0 sales for $6,410 activity.

The stock of Biotime Incorporated (NYSEMKT:BTX) registered an increase of 7.71% in short interest. BTX’s total short interest was 7.31 million shares in September as published by FINRA. Its up 7.71% from 6.78 million shares, reported previously. With 273,600 shares average volume, it will take short sellers 27 days to cover their BTX’s short positions. The short interest to Biotime Incorporated’s float is 11.36%.

The stock decreased 0.70% or $0.02 on September 15, reaching $2.85. About 565,682 shares traded or 107.46% up from the average. BioTime, Inc. (NYSEMKT:BTX) has risen 22.71% since September 17, 2016 and is uptrending. It has outperformed by 6.01% the S&P500.

BioTime, Inc. is a clinical-stage biotechnology firm focused on developing and commercializing products addressing degenerative diseases. The company has market cap of $330.04 million. The Company’s clinical programs are based on two platform technologies: pluripotent stem cells and cell/drug delivery platform technologies. It has a 4.71 P/E ratio. The foundation of its cell delivery platform is its HyStem cell and drug delivery matrix technology.

More notable recent BioTime, Inc. (NYSEMKT:BTX) news were published by: Seekingalpha.com which released: “BioTime: 3-D Retinal Tissue Licensing Agreement” on February 23, 2017, also Businesswire.com with their article: “Two Key BioTime Patents Providing Protection to OpRegenĀ® Remain Upheld” published on September 14, 2017, Reuters.com published: “BioTime’s Renevia succeeds in pivotal European facial wasting trial” on June 14, 2017. More interesting news about BioTime, Inc. (NYSEMKT:BTX) were released by: Businesswire.com and their article: “BioTime Forms New Subsidiary AgeX Therapeutics, Inc. to Develop its Programs …” published on April 06, 2017 as well as Seekingalpha.com‘s news article titled: “BioTime Inc.: Sifting Through Numerous Trials For Potential Opportunities” with publication date: May 01, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.